Safe group announces sales of €1,418 million, up 31% in the first quarter of 2022
13 April 2022 - 5:45PM
Safe group announces sales of €1,418 million, up 31% in the first
quarter of 2022
Safe group announces sales of €1,418
million, up 31% in the first quarter of
2022
- Return to pre-covid growth level (Q4 2019),
- Safe Orthopaedics: direct sales +34%, indirect sales +33%
- Safe Medical: +26% compared to Q1 2021.
|
|
|
|
Eragny-sur-Oise, France, April 13, 2022
at 5:45 p.m. CET - Safe (FR0013467123 - ALSAF), a company
specializing in the design, manufacture and marketing of
ready-to-use technologies for back surgery, particularly safe for
emergency vertebral fractures, today announced its first quarter
2022 revenue and cash position.
In thousands of euros |
Q1 2022(3 months) |
Q1 2021(3 months) |
2022/2021 |
Direct sales (FR, Ger, UK, USA) |
585 |
437 |
+34% |
Indirect sales |
343 |
258 |
+33% |
Production subcontracting sales |
490 |
389 |
+26% |
Total sales* |
1 418 |
1 084 |
+31% |
In the first quarter of 2022, the Safe Group's
sales totaled €1,428k, showing strong growth of +31% compared to
the first quarter of 2021, despite a health crisis still present in
indirect markets. This quarterly sales figure is the second
strongest quarterly sales performance after Q4 2019, which recorded
sales of €1,502k.
Safe Orthopaedics sales were up +33% compared to
Q1 2021 to €1,013k, driven by equivalent growth on direct and
indirect sales of 34% and 33% respectively.
While French sales were stable compared to Q1
2021, they showed strong growth in the United Kingdom, Germany and
the United States. Growth in Germany was supported by the recent
agreement signed with the Clinicpartner buying group. The United
States became the second largest direct sales region after one year
of activity.
Indirect sales have returned to growth at
€402,000, up 33% compared to Q1 2021, despite the Asia-Pacific
region still being impacted by the health crisis. Also,
distribution in Japan is slowed down by the sale of the Kisco
assets of the Otsuka group to the Teijin group in February
2022.
The new Sycamore and Hickory technologies are
being rolled out commercially and are contributing to growth in the
French and German markets, which were given priority for marketing
in the first half of the year, pending their approval in the United
States and their availability to indirect markets.
Safe Medical's business grew by 26% (to €490k)
compared with the first quarter of 2021. This growth was mainly
generated by long-standing customers, who are repositioning Safe
Medical as a strategic supplier and entrusting it with an
increasing number of integrated projects (complete services
including sterile packaging).
"This first quarter of 2022 shows the full
potential of the Group, with double-digit growth in Safe
Orthopaedics and Safe Medical, with the covid-19 health crisis
having less and less impact on our commercial execution. The
adoption of our technologies in the German and U.S. markets,
respectively the largest European and global markets, is
accelerating Safe Orthopaedics' sales, while Safe Medical is being
qualified as an increasingly strategic supplier by its historical
customers", comments Pierre Dumouchel,
Chairman and CEO and co-founder of Safe Orthopaedics. "The
synergy of our Safe Orthopaedics and Safe Medical entities is fully
used for sustained innovation: the commercial rollouts of Sycamore
and Hickory will continue to accelerate Franco-German sales in the
second quarter and should be available internationally by the
second half of the year. The evaluation of SORA is proceeding in
line with our expectations and the implementation of two new units
is planned in France in the second quarter before being offered to
the German and US markets by the end of 2022”.
Cash flow
With a significant refinancing of Safe SA of
€8.4 million at the end of the year, paid in monthly instalments of
€400,000, and the payment of the remaining €400,000 of the €0.8
million stimulus package, the Group's unaudited cash position stood
at €652,000 at 31 March 2022.
Agenda financier
Financial communication |
Date1 |
Annual results 2021 |
29 April 2022 |
Revenue 1st semester 2022 |
7 July 2022 |
Results 1st semester 2022 |
29 September 2022 |
Revenue 3rd quarter 2022 |
06 October 2022 |
Revenue 2nd semester 2022 |
10 January 2023 |
About Safe Group
Safe Group is a French medical technology group
that brings together Safe Orthopaedics, a pioneer in ready-to-use
technologies for spinal column pathologies, and Safe Medical
(formerly LCI Medical), a subcontractor of medical devices for
orthopedic surgery. The group employs approximately 150 people.
Safe Orthopaedics develops and manufactures kits
combining sterile implants and single-use instruments, available at
any time to the surgeon. These technologies are part of a minimally
invasive approach aimed at reducing the risk of contamination and
infection, for the benefit of the patient and with a positive
impact on hospitalization times and costs. Protected by 18
patent families, SteriSpineTM kits are CE marked and FDA approved.
Safe Orthopaedics is headquartered in the Paris region (95610
Eragny-sur-Oise) and has subsidiaries in the United Kingdom,
Germany, the United States and the Lyon region
(Fleurieux-sur-l'Arbresle).
For more information:
www.safeorthopaedics.com
Safe Medical produces implantable medical
devices and ready-to-use instruments. It has an innovation center
and two production sites in France (Fleurieux-sur-l'Arbresle,
69210) and in Tunisia, offering numerous industrial services:
design, industrialization, machining, finishing and sterile
packaging. Supported by the French stimulus plan in 2020, the
companý is investing in additive printing and will be operational
in 2022 on this new technology.
For more information: www.safemedical.fr
Contacts Safe
Group
François-Henri Reynaud
Chief Financial and Administrative
Officer
Phone: +33 (0)1 34 21 50
00
investors@safeorthopaedics.com
Press RelationsUlysse
CommunicationPierre-Louis Germain / +33 (0)6 64 79
97 61 / plgermain@ulysse-communication.com Bruno
Arabian / +33 (0)6 87 88 47 26 /
barabian@ulysse-communication.com
1Note (*) : All publications will be made after the close of the
markets. Information subject to change.
- 20220413 - CP_sales Q1_PDM
SAFE (EU:ALSAF)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
SAFE (EU:ALSAF)
Historical Stock Chart
Von Jul 2023 bis Jul 2024